Table 3.

Dose modification, delay, or discontinuation of study drug in North America

A+AVDABVD
(n = 249)(n = 240)
Action, n (%)BVDoxorubicinVinblastineDacarbazineBleomycinDoxorubicinVinblastineDacarbazine
No action taken98 (39)144 (58)134 (54)147 (59)114 (48)156 (65)149 (62)158 (66)
Action on study druga151 (61)105 (42)115 (46)102 (41)126 (53)84 (35)91 (38)82 (34)
 Dose reduced79 (32)9 (4)26 (10)10 (4)2 (<1)8 (3)20 (8)6 (3)
 Dose heldb28 (11)1 (<1)4 (2)022 (9)1 (<1)4 (2)1 (<1)
 Dose delayedc86 (35)93 (37)92 (37)88 (35)65 (27)70 (29)73 (30)70 (29)
 Dose discontinued30 (12)14 (6)18 (7)14 (6)63 (26)4 (2)9 (4)4 (2)
No alternative frontline regimen243243243243238238238238
6 cycles randomized regimen175 (70)213 (86)207 (83)216 (87)150 (63)215 (90)211 (88)212 (88)
  • Abbreviation: BV, brentuximab vedotin.

  • aSubjects recording the same action on study drug multiple times within a cycle or overall will be counted only once in the respective summary.

  • bHold indicates a dose that was skipped before restarting in the subsequent treatment round.

  • cDelay indicates doses administered after the protocol-specified treatment window for a cycle.